Anne Boerekamps1, Astrid M Newsum2,3, Colette Smit4, Joop E Arends5, Clemens Richter6, Peter Reiss3,4,7, Bart J A Rijnders1, Kees Brinkman8, Marc van der Valk3. 1. Department of Internal Medicine and Infectious Diseases, Erasmus Medical Center, Rotterdam. 2. Department of Infectious Diseases Research and Prevention, Public Health Service of Amsterdam. 3. Division of Infectious Diseases, Amsterdam Infection and Immunity Institute, Academic Medical Center. 4. Stichting HIV Monitoring, Amsterdam. 5. Department of Internal Medicine, Section Infectious Diseases, University Medical Center Utrecht. 6. Department of Internal Medicine and Infectious Diseases, Rijnstate Hospital, Arnhem. 7. Department of Global Health, Academic Medical Center and Amsterdam Institute for Global Health and Development. 8. Department of Internal Medicine and Infectious Diseases, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.
Abstract
Background: The Netherlands has provided unrestricted access to direct-acting antivirals (DAAs) since November 2015. We analyzed the nationwide hepatitis C virus (HCV) treatment uptake among patients coinfected with human immunodeficiency virus (HIV) and HCV. Methods: Data were obtained from the ATHENA HIV observational cohort in which >98% of HIV-infected patients ever registered since 1998 are included. Patients were included if they ever had 1 positive HCV RNA result, did not have spontaneous clearance, and were known to still be in care. Treatment uptake and outcome were assessed. When patients were treated more than once, data were included from only the most recent treatment episode. Data were updated until February 2017. In addition, each treatment center was queried in April 2017 for a data update on DAA treatment and achieved sustained virological response. Results: Of 23574 HIV-infected patients ever linked to care, 1471 HCV-coinfected patients (69% men who have sex with men, 15% persons who [formerly] injected drugs, and 15% with another HIV transmission route) fulfilled the inclusion criteria. Of these, 87% (1284 of 1471) had ever initiated HCV treatment between 2000 and 2017, 76% (1124 of 1471) had their HCV infection cured; DAA treatment results were pending in 6% (92 of 1471). Among men who have sex with men, 83% (844 of 1022) had their HCV infection cured, and DAA treatment results were pending in 6% (66 of 1022). Overall, 187 patients had never initiated treatment, DAAs had failed in 14, and a pegylated interferon-alfa-based regimen had failed in 54. Conclusions: Fifteen months after unrestricted DAA availability the majority of HIV/HCV-coinfected patients in the Netherlands have their HCV infection cured (76%) or are awaiting DAA treatment results (6%). This rapid treatment scale-up may contribute to future HCV elimination among these patients.
Background: The Netherlands has provided unrestricted access to direct-acting antivirals (DAAs) since November 2015. We analyzed the nationwide hepatitis C virus (HCV) treatment uptake among patients coinfected with human immunodeficiency virus (HIV) and HCV. Methods: Data were obtained from the ATHENA HIV observational cohort in which >98% of HIV-infectedpatients ever registered since 1998 are included. Patients were included if they ever had 1 positive HCV RNA result, did not have spontaneous clearance, and were known to still be in care. Treatment uptake and outcome were assessed. When patients were treated more than once, data were included from only the most recent treatment episode. Data were updated until February 2017. In addition, each treatment center was queried in April 2017 for a data update on DAA treatment and achieved sustained virological response. Results: Of 23574 HIV-infectedpatients ever linked to care, 1471 HCV-coinfectedpatients (69% men who have sex with men, 15% persons who [formerly] injected drugs, and 15% with another HIV transmission route) fulfilled the inclusion criteria. Of these, 87% (1284 of 1471) had ever initiated HCV treatment between 2000 and 2017, 76% (1124 of 1471) had their HCV infection cured; DAA treatment results were pending in 6% (92 of 1471). Among men who have sex with men, 83% (844 of 1022) had their HCV infection cured, and DAA treatment results were pending in 6% (66 of 1022). Overall, 187 patients had never initiated treatment, DAAs had failed in 14, and a pegylated interferon-alfa-based regimen had failed in 54. Conclusions: Fifteen months after unrestricted DAA availability the majority of HIV/HCV-coinfectedpatients in the Netherlands have their HCV infection cured (76%) or are awaiting DAA treatment results (6%). This rapid treatment scale-up may contribute to future HCV elimination among these patients.
Authors: Kathleen M Ward; Oluwaseun Falade-Nwulia; Juhi Moon; Catherine G Sutcliffe; Sherilyn Brinkley; Taryn Haselhuhn; Stephanie Katz; Kayla Herne; Lilian Arteaga; Shruti H Mehta; Carl Latkin; Robert K Brooner; Mark S Sulkowski Journal: Open Forum Infect Dis Date: 2019-04-09 Impact factor: 3.835
Authors: Chunki Fong; Pedro Mateu-Gelabert; Courtney Ciervo; Benjamin Eckhardt; Yesenia Aponte-Melendez; Shashi Kapadia; Kristen Marks Journal: Drug Alcohol Depend Date: 2021-02-13 Impact factor: 4.492
Authors: Maria A Corcorran; Natasha Ludwig-Baron; Debbie M Cheng; Dmitry Lioznov; Natalia Gnatienko; Gregory Patts; Kaku So-Armah; Elena Blokhina; Sally Bendiks; Evgeny Krupitsky; Jeffrey H Samet; Judith I Tsui Journal: AIDS Behav Date: 2021-03-17
Authors: Oluwaseun Falade-Nwulia; Paul Sacamano; Sean D McCormick; Cui Yang; Greg Kirk; David Thomas; Mark Sulkowski; Carl Latkin; Shruti H Mehta Journal: Int J Drug Policy Date: 2020-03-02
Authors: Rachel Sacks-Davis; Joseph S Doyle; Andri Rauch; Charles Beguelin; Alisa E Pedrana; Gail V Matthews; Maria Prins; Marc van der Valk; Marina B Klein; Sahar Saeed; Karine Lacombe; Nikoloz Chkhartishvili; Frederick L Altice; Margaret E Hellard Journal: J Int AIDS Soc Date: 2018-04 Impact factor: 5.396
Authors: Tamara Sonia Boender; Colette Smit; Ard van Sighem; Daniela Bezemer; Catriona J Ester; Sima Zaheri; Ferdinand W N M Wit; Peter Reiss Journal: BMJ Open Date: 2018-09-24 Impact factor: 2.692